Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2.5 mg Saxagliptin, Twice Daily, in Combination With Metformin IR in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin IR Alone.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Saxagliptin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 15 Dec 2011 Actual patient number is 166 according to ClinicalTrials.gov.
- 15 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Dec 2009 Planned end date changed from 1 Jan 2010 to 1 Feb 2010 as reported by ClinicalTrials.gov.